Cybin D/B/A Helus Pharma (HELP)Healthcare | Biotechnology | Toronto, Canada | NasdaqGM
12.18 USD
-1.06
(-8.006%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 12.35 +0.17 (1.396%) ⇧ (Aug. 28, 2026, 7:52 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:17 a.m. EDT
The investment case here is structurally broken. The company is hemorrhaging cash with negative free cash flow and a massive burn rate, funded by a recent $50M raise that barely covers the bleeding. Fundamentally, the business is failing; it has posted four consecutive years of declining revenue, dragging the total return over the last five years down by roughly 64%. The balance sheet is fragile, with a book value of mere cents per share against a trading price that is absurdly inflated relative to assets. While analysts offer a 'strong buy' rating based on a distant, speculative clinical trial readout, the current reality is a value trap with deteriorating fundamentals. The options market confirms this pessimism, with traders buying insurance at strikes far below the current price, signaling a high probability of further decline. There is no dividend to provide income, and the lack of consistent growth makes holding this stock a gamble on a future event that hasn't happened yet. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.305018 |
| AutoETS | 0.307753 |
| MSTL | 0.313150 |
| AutoTheta | 0.329197 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 25.34 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.298 |
| Excess Kurtosis | -1.09 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 889,872,960 |
| Forward P/E | -6.64 |
| Beta | 0.57 |
| Previous Name | Cybin, Inc. |
| Website | https://www.helus.com |
As of Aug. 22, 2026, 2:17 a.m. EDT: Speculators are heavily positioned for downside protection with deep out-of-the-money puts dominating open interest across nearly all expirations, while call volume is negligible and concentrated near the money. This structure indicates a market consensus expecting further price weakness rather than a catalyst-driven rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.1217949 |
| Address1 | 100 King Street West |
| Address2 | Suite 5600 |
| All Time High | 128.44 |
| All Time Low | 2.964 |
| Ask | 11.87 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,581,430 |
| Average Daily Volume3 Month | 1,598,853 |
| Average Volume | 1,598,853 |
| Average Volume10Days | 1,581,430 |
| Beta | 0.565 |
| Bid | 6.79 |
| Bid Size | 2 |
| Book Value | 0.053712677 |
| City | Toronto |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 12.18 |
| Current Ratio | 10.969 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 13.22 |
| Day Low | 12.13 |
| Display Name | Cybin |
| Earnings Timestamp | 1,786,710,600 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -166,936,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -9.59 |
| Enterprise Value | 1,600,852,096 |
| Eps Current Year | -3.7055 |
| Eps Forward | -1.8336006 |
| Eps Trailing Twelve Months | -3.73 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.5099 |
| Fifty Day Average Change | 3.6701002 |
| Fifty Day Average Change Percent | 0.43127418 |
| Fifty Two Week Change Percent | 112.1795 |
| Fifty Two Week High | 14.35 |
| Fifty Two Week High Change | -2.17 |
| Fifty Two Week High Change Percent | -0.15121952 |
| Fifty Two Week Low | 3.76 |
| Fifty Two Week Low Change | 8.42 |
| Fifty Two Week Low Change Percent | 2.2393618 |
| Fifty Two Week Range | 3.76 - 14.35 |
| Financial Currency | CAD |
| First Trade Date Milliseconds | 1,568,381,400,000 |
| Float Shares | 111,069,820 |
| Forward Eps | -1.8336006 |
| Forward P E | -6.642668 |
| Free Cashflow | -82,425,128 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 100 |
| Fullday Change | -1.06 |
| Fullday Change Percent | -8.00604 |
| Fullday Price | 12.35 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11205 |
| Held Percent Institutions | 0.43737 |
| Implied Shares Outstanding | 73,060,172 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-01-05 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,774,915,200 |
| Last Split Date | 1,726,704,000 |
| Last Split Factor | 1:38 |
| Long Business Summary | Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada. |
| Long Name | Cybin D/B/A Helus Pharma |
| Market | us_market |
| Market Cap | 889,872,960 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_666815486 |
| Most Recent Quarter | 1,604,102,400 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -171,204,000 |
| Next Fiscal Year End | 1,806,451,200 |
| Non Diluted Market Cap | 967,847,834 |
| Number Of Analyst Opinions | 9 |
| Open | 13.18 |
| Operating Cashflow | -140,792,992 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 908 764 8385 |
| Post Market Change | 0.17000008 |
| Post Market Change Percent | 1.3957313 |
| Post Market Price | 12.35 |
| Post Market Time | 1,787,961,134 |
| Prev Name | Cybin, Inc. |
| Previous Close | 13.24 |
| Price Eps Current Year | -3.287006 |
| Price Hint | 2 |
| Price To Book | 226.76212 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.757 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -1.06 |
| Regular Market Change Percent | -8.00604 |
| Regular Market Day High | 13.22 |
| Regular Market Day Low | 12.13 |
| Regular Market Day Range | 12.13 - 13.22 |
| Regular Market Open | 13.18 |
| Regular Market Previous Close | 13.24 |
| Regular Market Price | 12.18 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,451,330 |
| Return On Assets | -0.44382998 |
| Return On Equity | -0.86939 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 73,060,172 |
| Shares Percent Shares Out | 0.0438 |
| Shares Short | 3,153,149 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,257,009 |
| Short Name | Cybin Inc. |
| Short Ratio | 1.58 |
| Source Interval | 15 |
| State | ON |
| Symbol | HELP |
| Target High Price | 69.9518 |
| Target Low Price | 15.255737 |
| Target Mean Price | 41.300144 |
| Target Median Price | 45.447086 |
| Total Cash | 206,357 |
| Total Cash Per Share | 0.002 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.73 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.578275 |
| Two Hundred Day Average Change | 5.601725 |
| Two Hundred Day Average Change Percent | 0.8515492 |
| Type Disp | Equity |
| Volume | 1,451,330 |
| Website | https://www.helus.com |
| Zip | M5X 1C9 |